REGULATION OF BONE FORMATION IN RENAL OSTEODYSTROPHY

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 肾性骨营养不良是一系列骨骼疾病，从继发性甲状旁腺功能亢进症(2HPT)的高周转率病变(血清甲状旁腺激素(PTH)水平显著升高)到低周转率病变(如动力骨病)，血清甲状旁腺激素水平正常或轻度升高。在终末期肾病(ESRD)的儿童中，2HPT仍然是最常见的疾病，通常需要骨化三醇治疗。对于患有2HPT的患者，通常使用每周两次的大剂量骨化三醇来降低血清PHT水平，降低骨形成和骨转换，但动态肾性骨营养不良可能在治疗8至12个月后发生。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Renal osteodystrophy is a spectrum of skeletal disorders ranging from high-turnover lesions of secondary hyperparathyroidism (2HPT), in which serum parathyroid homornes (PTH) levels are substantially elevated, to low-turnover lesions such as adynamic bone, in which serum PTH levels are normal or minimally increased. In children with end-stage renal disease (ESRD), 2HPT remains the most common disorder, and treatment with calcitriol is often required. Large twice-weekly doses of calcitriol are commonly used to reduce serum PHT levels and lower bone formation and turnover in those patients with 2HPT, but adynamic renal osteodystrophy can develop after only eight to 12 months of treatment.